At the Wolfe Research Healthcare Conference, Gilead Sciences detailed launch plans for anito-cel, its CAR-T cell therapy for multiple myeloma.
Gilead is preparing to launch the therapy for fourth-line treatment at 200 U.S. centers. The launch is pending an FDA decision expected by the PDUFA date of December 23, 2026.
The company sees anito-cel as a significant growth driver and is targeting a filing for a second-line indication in 2027. Executives said the fourth-line market is worth $3.5 billion. The potential second-line market could reach $12 billion.